If you are referring to slide 6, I think the point was
- ACL have FDA priority
- first to file and in over 2 yrs ago
- OTHERS have to deal with long approval times, hence a positive for ACL - that's why the heading was "High barriers to entry for generic"
Your thread heading is misleading.
- Forums
- ASX - By Stock
- TSN
- not good - alchemia admits fda approval delay
not good - alchemia admits fda approval delay, page-3
-
-
- There are more pages in this discussion • 30 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online